Abstract

 This comprehensive review summarises the pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension 0.6% against moxifloxacin 0.3% solution and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase 2(also called DNA gyrase) and topoisomerase 4. Ocular pharmacokinetic studies have shown that besifloxacin achieves high, sustained concentrations in the tear fluid and conjunctiva following topical administration, with negligible systemic exposure. Large randomized, controlled clinical trials have established the efficacy and safety of besifloxacin administered 3 times daily for 5 days for treatment of acute bacterial conjunctivitis in both adults and children.

In our study, we are trying to compare the efficacy of besifloxacin vs. moxifloxacin topical for simple bacterial keratitis without perforation or any other complication. Patients with other systemic diseases like diabetes, collagen diseases, immunocompromised state or any other infectious disease were excluded from our study. All culture positive acute bacterial keratitis coming to our tertiary institute were selected randomly. Alternatively we treated them with either besifloxacin or moxifloxacin. Then followed them on 3,7,15,30 days respectively, noting all signs, symptoms, slitlamp biomicroscopy, visual acuity, slitlamp photography, patient’s overall satisfaction etc.

We found both the drugs equally effective, but doses frequency less in besifloxacin group, patient reliability and comfort also more in besifloxacin group.

Keywords- Topical, Besifloxacin, Moxifloxacin,Bacterial Keratitis.